Stereotaxis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen reiterated a Buy rating on the stock and has a $5.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Stereotaxis’s strategic advancements and potential for future growth. The recent FDA 510K clearance for the GenesisX robotic magnetic navigation system is a pivotal development, as it enhances the accessibility and scalability of Stereotaxis’s technology. This clearance is expected to drive broader adoption in the US and EU markets starting in 2026, marking a significant milestone in the company’s transformation.
Additionally, Stereotaxis is evolving from a hardware-centric manufacturer to a diversified medtech innovator. This shift is characterized by the successful commercialization of capital systems, the introduction of three high-margin catheter portfolios, and transformative digital innovations that support a smart cath lab vision. These strategic changes are expected to diversify revenue streams and position Stereotaxis for sustainable growth, underpinning Jennings’s optimistic outlook and Buy rating.
According to TipRanks, Jennings is a 2-star analyst with an average return of 0.6% and a 46.39% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Medtronic, TransMedics Group, and Boston Scientific.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $4.00 price target.